IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Every figure this model derived for IOVA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 32,213,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 297,674,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 464,257,000 AssetsCurrent 2026-06-30
current liabilities 106,848,000 LiabilitiesCurrent 2026-06-30
equity 736,045,000 StockholdersEquity 2026-06-30
ocf -264,182,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 324,969,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 46,719,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up IOVA on one particular measure came for.

RatioValue
cash operating margin-74.18
current ratio4.35
current ratio reported4.35
dilution pct23.29
fcf margin-91.21
operating margin-92.72
owner earnings margin-105.58
revenue growth34.55
revenue growth per share9.13
roic-54.18
rule of 40-58.17
sbc pct revenue14.38

What to be careful about

What this model itself distrusts about IOVA's figures. Written by the derivation as it ran, not added afterwards.